BioToxTech Co

BioToxTech Co Debt / Assets

The Debt-to-Assets Ratio of BioToxTech Co (086040.KQ) as of Oct 22, 2026 is 0.09. In the previous year, Debt-to-Assets Ratio was 0.28 — a change of -69.77% (lower).

Debt / Assets

0.09

YoY

-69.77%

Last updated:

Debt-to-Assets Ratio of BioToxTech Co is 2025 0.09 . Debt-to-Assets Ratio of BioToxTech Co was 2024 0.28 . It decreases by -69.77% lower compared to the previous year.

The BioToxTech Co Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2018
0.27 KRW
Jan 1, 2019
0.28 KRW
Jan 1, 2020
0.19 KRW
Jan 1, 2021
0.17 KRW
Jan 1, 2022
0.27 KRW
Jan 1, 2023
0.30 KRW
Jan 1, 2024
0.28 KRW
Jan 1, 2025
0.09 KRW
The BioToxTech Co Debt / Assets history
YEARDebt / AssetsYoY
0.09-69.77%
0.28-5.56%
0.30+9.13%
0.27+62.19%
0.17-12.69%
0.19-29.83%
0.28+3.98%
0.27+3.75%
0.26-8.92%
0.28-9.63%
0.31+494.88%
0.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Debt-to-Assets Ratio of BioToxTech Co is 0.09 in 2025.

Debt-to-Assets Ratio of BioToxTech Co changed from 0.28 to 0.09, representing a -69.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — BioToxTech Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — BioToxTech Co